MarketsandMarkets

Pyrogen Testing Market - Global Forecast 2025, Global Industry Is Expecting to Grow at CAGR of 12.7%

North America is the largest regional market for pyrogen testing market in 2019

 

Northbrook, IL -- (SBWIRE) -- 02/04/2021 -- According to the new market research report "Pyrogen Testing Market by Product & Service (Assays, Kits, Reagents, Instruments, Services), Test Type (LAL, Chromogenic, Turbidimetric, Gel Clot, In Vitro, Rabbit), End User (Pharmaceutical, Biotechnology, Medical Device), Region-Global Forecast to 2025" published by MarketsandMarkets™, is projected to reach USD 1,689 million by 2025 from USD 927 million in 2020, at a 12.7% CAGR.

The growing awareness of food safety mainly drives growth in the pyrogen testing market, rising incidence of infectious diseases, increasing pandemics frequency, increasing R&D in the pharmaceutical and biotechnology industries, and growing focus on personalized medicine. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the pyrogen testing market.

Browse through 107market data tables and 36 figures spread across166pages and the in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=255266155

The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service segment, in 2019

Based on product & service, the pyrogen testing market is segmented into assays, kits, and reagents; instruments; and services. The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market in 2019. Thefrequent requirement of assays, kits, and reagents in large numbers compared to instruments and the rising preference for kit-based testing are the major factors driving this segment's growth.

LAL tests segment to register the highest growth rate during the forecast period

The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type. In 2019, the LAL tests segment accounted for the highest growth rate. This can be attributed to the rising need for innovative laboratory testing procedure and the increasing support for vaccine development.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the pyrogen testing market, by end user segment, in 2019

Based on end-users, the pyrogen testing market is segmented into pharmaceutical & biotechnology companies, medical device companies, and other end users. In 2019, pharmaceutical & biotechnology companies accounted for the largest share of the pyrogen testing market. High inclination towards outsourcing preclinical, clinical, and laboratory testing services, a large number of ongoing drug discovery activities, and the increasing number of R&D facilities globally are the major factors driving this segment's growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255266155

The pyrogen testing market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the pyrogen testing market. The large share of this region can be attributed to the rising prevalence of diseases, a growing number of drug approvals, increasing pharmaceutical drug pipelines, and growing consumer awareness about product safety.

The major players operating in this market are Charles River Laboratories, Inc. (US), Lonza (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), Associates of Cape Cod, Inc. (US), GenScript Biotech Corporation (China), bioMĂ©rieux SA (France), FUJIFILM Wako Pure Chemical Corporation (Japan), Eurofins Scientific (Luxembourg), WuXi AppTec (China), Hycult Biotech (Netherlands), Ellab A/S (Denmark), Microcoat Biotechnologie GmbH (Germany), InvivoGen (US), Nelson Laboratories, LLC (US), Almac Group (UK), Pacific Biolabs (US), STERIS plc (US), Accugen Laboratories, Inc. (US), TOXIKON (US), Minerva Analytix GmbH (Germany), Indoor Biotechnologies, Inc. (US), Creative Bioarray (US), Lucideon Limited (UK), and North American Science Associates, Inc. (US).